Table 1.
Clinical characteristics according to the occurrence of primary outcome
| Total (n = 311) | No event (n = 268) | Event (n = 43) | P value | |
|---|---|---|---|---|
| Age (years) a | 55 (48, 71) | 54 (47, 68) | 77 (55, 85) | <0.001 |
| Male sex (%) | 81 | 82 | 79 | 0.382 |
| Cardiovascular risk factors | ||||
| BMI, (kg/m2) a | 27.3 (25, 30) | 27.5 (25, 30) | 26.7 (24, 29) | 0.540 |
| Hypertension (%) | 57 | 55 | 72 | 0.018 |
| Diabetes (%) | 26 | 23 | 42 | 0.005 |
| Dyslipidaemia (%) | 51 | 50 | 58 | 0.458 |
| Active smoker (%) | 40 | 43 | 26 | 0.390 |
| MI index event | ||||
| ST‐elevation MI (%) | 65 | 66 | 61 | 0.908 |
| Successful revascularization (TIMI 3) (%) | 94 | 95 | 84 | 0.002 |
| Killip class ≥ II (%) | 23 | 15 | 67 | <0.001 |
| GRACE risk score a | 133 (114, 171) | 129 (111, 159) | 196 (144, 238) | <0.001 |
| Charlson Comorbidity Index a | 4 (2, 5) | 3 (2, 5) | 6 (5, 7) | <0.001 |
| Laboratory parameters | ||||
| NT‐proBNP (pg/mL) a | 903 (363, 2415) | 617 (215, 1541) | 5701 (2115, 14 714) | <0.001 |
| Troponin‐I (at 24 h) a | 8.8 (1, 38) | 6.9 (1, 32) | 29.1 (6, 88) | <0.001 |
| GFR (mL/min/1.73 m2) a | 91 (73, 103) | 93 (78, 104) | 52 (33, 78) | <0.001 |
| Total cholesterol (mg/dL) a | 177 (147, 206) | 179 (148, 209) | 158 (137, 192) | 0.028 |
| Triglycerides (mg/dL) a | 122 (88, 169) | 122 (88, 169) | 123 (89, 169) | 0.999 |
| Echocardiographic findings | ||||
| LVEF at discharge (%) a | 57 (46, 65) | 58 (48, 65) | 43 (36, 58) | <0.001 |
| LVEF < 50% (%) | 33 | 27 | 67 | <0.001 |
| Medications at discharge | ||||
| β‐Blocker (%) | 83 | 83 | 78 | 0.556 |
| ACE inhibitor or ARB (%) | 82 | 82 | 83 | 0.967 |
| Mineralocorticoid antagonist (%) | 37 | 10 | 33 | <0.001 |
| High intensity statin (%) | 97 | 97 | 92 | 0.025 |
ACE, angiotensin‐converting enzyme; ARB, angiotensin‐II receptor blocker; BMI, body mass index; GFR, glomerular filtration rate; LVEF, left ventricular ejection fraction; MI, myocardial infarction.
a
Median (25th and 75th quartile cut‐point).